Abstract: A method is disclosed for preventing recurrence of duodenal ulcer associated with Campylobacter pylori infection in a patient suffering from duodenal ulcer disease associated with Campylobacter pylori infection by administering a pharmaceutically acceptable bismuth compound; a first antibiotic selected from the group consisting of tetracycline and penicillins and second antibiotic which is metronidazole.
Abstract: Immunoreactive cells sensitized for an antigenic marker associated with a malignant tumor are prepared in vitro by collecting the tumor patient's own mononuclear cells, depleting suppressor T-cells, suspending the mononuclear cells with serum, preferably autologous, and culturing the cells under conditions to activate and immunize the patient's mononuclear cells against the patient's tumor. Methods of treatment and immunized cells in pharmaceutical presentations are described.
Abstract: A method of immunotherapy for treating diseases and disorders which involve cellular Fc receptor mediated immune responses in humans and animals is disclosed. Abnormal or undesirable cellular Fc receptor mediated immune reactions are beneficially altered by locally or systemically administering an exogenous Fc receptor polypeptide, in particular a multivalent protein having in its molecule several Fc receptor sites, such as staphylococcus protein A, or monovalent Fc receptor possessing only a single Fc receptor site.
Abstract: A pharmaceutical dosage form for administration of medicament to fish has an outer layer of animal or vegetable material surrounding at least one inner chamber containing one or more biologically active agents. The outer layer, which is composed of animal and/or vegetable material and/or an aqueous extract from marine materials, and an optional binder, is substantially impermeable to water and the medicament. The chamber is filled with the active agent in a viscous pharmaceutical formulation to improve the bioavailability and stability of the active agent. The chamber may be partly filled with gas. The buoyancy of the dosage form in water is manipulable by adjusting the volume and contents of the inner chamber.
Type:
Grant
Filed:
January 30, 1992
Date of Patent:
December 8, 1992
Assignee:
Apothe Kernes Laboratorium A.S.
Inventors:
Odd F. Ellingsen, Kjell E. Nordby, Knut E. Rasmussen
Abstract: A method of treating pulmonary emphysema or adult respiratory distress syndrome in a subject in need thereof which comprises administering to the subject an effective amount of WS7622A, B, C and/or D, derivatives thereof, or their pharmaceutically acceptable salt.
Abstract: A therapeutic preparation for ulcers contains as a primary ingredient a compound having an aldose reductase inhibitory activity and can accelerate dermal metabolism. That compound may be d-6-fluoro-2,3-dihydro-2',5'-dioxo-spiro [4H-1-benzopyran-4,4'-imidazolidine]-2-carboxyamide, d-2-chloromethyl-6-fluoro-2,3-dihydro-spiro [4H-1-benzopyran-4,4'-imidazolidine]-2',5'-dione and d-2-bromomethyl-6-fluoro-2,3-dihydro-spiro [4H-1-benzopyran-4,4'-imidazolidine]-2',5'-dione.
Abstract: According to the invention, it has been found that plant cytokinins are effective in treating inflammation in mammals, such as humans. The plant cytokinins are effective to treat the inflammation, to accelerate healing of lesions, and to provide substantially immediate relief of pain, itching, and other immunological responses resulting from inflammation. The plant cytokinin is administered to the mammal in a suitable pharmaceutical preparation.Particular plant cytokinins which have been tested include trans-zeatin (trans-6-(4-hydroxy-3-methyl(but-2-enyl)-aminopurine)), 6-benzyl-adenine (6-benzylaminopurine), and kinetin (6-furfurylaminopurine).A composition for topical use in accordance with the method comprises an effective amount of the plant cytokinin in a carrier suitable for topical application to the human skin, for example, hydrophilic ointment, isopropyl alcohol, or a powder formulation.
Abstract: The invention relates to compositions for the parenteral administration of an essentially uniform and continuous amount of a peptide, which has a molecular weight of up to about 5,000, over an extended period of time. The peptide composition comprises a compacted and partially coated C.sub.10 -C.sub.20 fatty acid salt of the peptide. Examples of peptides useful in the invention includehis-D-trp-ala-trp-D-phe-lys-NH.sub.2,bradykinin, luteinizing hormone releasing hormone, growth releasing factor and poly-l-lysine. The invention also relates to the preparation and administration of said peptide compositions.
Abstract: A method for reversing or preventing the onset of tolerance and the development of extrapyramidal side effects in humans due to prolonged treatment with neuroleptics, comprising including S-adenosyl-L-methionine (SAMe) in the treatment regime. By utilizing SAMe in combination with tolerance-inducing neurolepitcs to maintain a minimum dosage of the drug while retaining its efficacy, the potential for the development of neuroleptic-induced, extrapyramidal side effects is minimized.
Type:
Grant
Filed:
August 31, 1990
Date of Patent:
August 11, 1992
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services
Abstract: A sprayable aqueous disinfecting composition for disinfecting hard surfaces comprising 20 to 30% by weight of a mixture of ethyl alcohol and isopropyl alcohol in a weight ratio of 1:2 to 2:1, 0.05 to 0.5% by weight of a mixture of a primary or secondary C.sub.10-18 -alkane sulfonate and/or a C.sub.10-18 -alkyl sulfate with a C.sub.10-14 -alkyl ether sulfate, a pH adjusting agent for adjusting the pH in the range of 2 to 6 or 8 to 12, and the remainder to 100% by weight water.
Abstract: The subject invention involves pharmaceutical compositions comprising a sulfated glyceroglucolipid having the structure: ##STR1## wherein n is an integer of from 1 to about 5, R is hydrogen or C.sub.1 -C.sub.24 acyl or alkyl, R' is hydrogen or C.sub.1 -C.sub.24 acyl or alkyl, and M.sup.+ is a cationic moiety, and methods of treating or preventing gastroduodenal diseases or disorders caused by or associated with H. pylori by administering such compounds.
Abstract: The invention concerns a method for the treatment of Parkinson's Disease. The method comprises administering a catechol-O-methyl-transferase inhibiting amount of a compound having the formula I ##STR1## wherein R.sub.1 and R.sub.2 independently represent hydrogen, alkylcarbamoyl of 2 to 5 carbon atoms or alkylcarbonyl of 2 to 5 carbon atoms, X represents nitro or cyano and R.sub.3 represents ##STR2## wherein R.sub.4 represents cyano or alkylcarbonyl of 2 to 5 carbon atoms and R.sub.5 represents cyano; alkylcarbonyl of 2 to 5 carbon atoms; or carbamoyl which is unsubstituted or substituted with alkyl of 1 to 8 carbon atoms, or hydroxyalkyl of 1 to 8 carbon atoms or pharmaceutically acceptable salts or esters thereof; and a sufficient amount of levodopa to treat Parkinson's Disease. A peripheral decarboxylase inhibitor such as carbidopa or benzerazide is also preferably administered.
Type:
Grant
Filed:
September 25, 1990
Date of Patent:
May 12, 1992
Assignee:
Orion-yhtyma Oy
Inventors:
Reijo Backstrom, Kalevi E. Heinola, Erkki J. Honkanen, Seppo K. Kaakkola, Pekka J. Kairisalo, Inge-Britt Y. Linden, Pekka I. Mannisto, Erkki A. O. Nissinen, Pentti Pohto, Aino K. Pippuri, Jarmo Pystynen
Abstract: Treating human beings with pharmacological quantities of DHEA results in their blood having increased serum DHEA and DHEA-S and lower rates of platelet aggregation. Reducing the rate of platelet aggregation can significantly reduce the incidence or morbidity and mortality from vascular events such as myocardial infarction and stroke, as well as reduce the occurrence of restenosis following vascular interventions. The concentration of DHEA and DHEA-S in the blood and the pre-incubation time of DHEA and DHEA-S with the blood will affect its impact on platelet aggregation. Hence, prior treatment of patients who are at risk with DHEA may produce the most beneficial affects. In addition, treatment of blood with DHEA-S reduces thromboxane production. Thromboxane is produced after platelets are subjected to many different types of agonists and is responsible for recruiting other platelets to aggregate and form a thrombus; therefore, blocking the production of thromboxane will reduce or prevent platelet aggregation.
Type:
Grant
Filed:
February 8, 1991
Date of Patent:
May 5, 1992
Assignee:
Virginia Commonwealth University
Inventors:
David M. Eich, Robert Jesse, John Nestler
Abstract: A pharmaceutical composition is disclosed comprising (-)-cis-2-methylspiro(1,3-oxathiolan-5,3')quinuclidine, and/or the pharmaceutically compatible acid addition salts thereof, together with at least one of physostigmine, tetrahydroaminoacridine, choline, lecithin, piracetam, aniracetam, pramiracetam, oxiracetam, 4-aminopyridine, 3,4-diaminopyridine, somatostatin, pirenzepine, N-methylatropine, N-butylscopolamine, scopolamine, clonidine, quanfamicine and Nerve Growth Factor. Also disclosed is a method for treating senile dementia of Alzheimer's type, which comprises coadministering to a patient in need thereof an effective dose of the spiro compound together with at least one other compound selected from those listed above.
Type:
Grant
Filed:
October 19, 1990
Date of Patent:
April 21, 1992
Assignee:
State of Israel, represented by the Prime Minister's office, Israel Institute for Biological Research
Inventors:
Abraham Fisher, Ishai Karton, Eliahu Heldman, Yona Grunfeld, Aharon Levy
Abstract: A method for the treatment of Acquired Immune Deficiency Syndrome is disclosed, which is based on the administration of a tellurium derivative of the formula: ##STR1## wherein Q is Te or Se; t is 1 or 0; u is 1 or 0; v is 1 or 0; R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, and R.sub.9 are the same or different and are independently selected from the group consisting of hydrogen, hydroxyalkyl of 1 to 5 carbons, hydroxy, alkyl of from 1 to 5 carbon atoms, halogen, haloalkyl of 1 to 5 carbon atoms, carboxy, alkylcarbonylalkyl of 2 to 10 carbons, alkanoyloxy of 1 to 5 carbon atoms, carboxyalkyl of 1 to 5 carbon atoms, acyl, amido, cyano, amidoalkyl of 1 to 5 carbons, N-monoalkylamidoalkyl of 2 to 10 carbons, N,N-dialkylamidoalkyl of 4 to 10 carbon, cyanoalkyl of 1 to 5 carbons, alkoxy of 1 to 5 carbon atoms, alkoxyalkyl of 2 to 10 carbons atoms and --COR.sub.10 wherein R.sub.10 is alkyl of from 1 to 5 carbons; and X is halogen.
Abstract: Improved metal complex-containing pharmaceutical agents are described which, as an additive, contain one or more complexing agents and/or one or more weak metal complex(es) or mixtures thereof.
Type:
Grant
Filed:
October 22, 1990
Date of Patent:
March 24, 1992
Assignee:
Schering Aktiengellschaft
Inventors:
Heinz Gries, Ulrich Speck, Hanns-Joachim Weinmann, Hans P. Niendorf, Wolfgang Seifert
Abstract: Compositions useful for thrombolytic therapy comprising a plasminogen activator such as tPA or streptokinase together with an imidazolium salt having the formula ##STR1## in a pharmaceutically acceptable carrier and methods for inhibiting hard clot formation or supplementing fibrinolytic therapy are described. The imidazolium salt also may be used with a platelet aggregation inhibitor or anticoagulant.
Type:
Grant
Filed:
April 29, 1991
Date of Patent:
March 24, 1992
Assignee:
Merck & Co., Inc.
Inventors:
John J. Baldwin, David C. Remy, David A. Claremon
Abstract: The present invention discloses a method of preparing activated killer monocytes for treating colorectal cancer. Activated killer monocytes are prepared in serum free medium in polypropylene containers.
Type:
Grant
Filed:
June 20, 1988
Date of Patent:
March 3, 1992
Assignee:
The United States of America as represented by the Department of Health and Human Services
Abstract: This invention provides anti-HBs monoclonal antibodies HBs 8Cl, HBs 18E9 and HBs 22B7, an anti-human IgM monoclonal antibody HIgM 10C9 and an anti-mumps virus monoclonal antibody MPV 10G3 capable of inhibiting nonspecific reaction in the reverse passive agglutination, hybridomas producing them, a method for sensitizing fixed hemocytes with anti-HBs monoclonal antibodies, a fixed hemocyte sensitized with them by the said method, a method for inhibiting the said nonspecific reaction by utilizing the said monoclonal antibodies and an assay for HBs antigen by appropriately combining the above.